Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

CytoDyn Inc. (OTCQX:CYDY) said Chairman Scott Kelly will also serve as CMO and head of business development. The company has treated 12 mild-to-moderate COVID-19 patients in a Phase II trial of its CCR5 antagonist, leronlimab; on Monday, it began enrolling patients with severe symptoms in a Phase IIb/III trial.

Collagenase-based therapies company BioSpecifics Technologies Corp. (NASDAQ:BSTC) said CEO Kevin Buchi has stepped down and Joseph Truitt will serve as interim CEO. Truitt was CEO of Achillion Pharmaceuticals Inc., which Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquired in January. ...